{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:45:44Z","timestamp":1792363544878,"version":"4.4.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Statins, as an important class of lipid-lowering drugs, play a key role in the prevention and treatment of cardiovascular diseases. However, with their widespread use in clinical practice, some adverse events have gradually emerged. In particular, the hepatotoxicity associated with statins use has become one of the clinical concerns that require sufficient attention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, we conducted a comprehensive and detailed analysis of the hepatotoxicity of statins based on the data of the US Food and Drug Administration Adverse Event Reporting System database from the first quarter (Q1) of 2004 to the Q1 of 2024 and used Reporting Odds Ratios and Empirical Bayes Geometric Mean to mine the signal of adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In this study, hepatic disorder related seven statins all exhibited positive signals. Through signal mining, we identified a total of 14,511 cases of adverse events associated with hepatic disorder caused by these statin drugs, with atorvastatin, simvastatin, and rosuvastatin occurring at a higher rate. A total of 148 positive signals related to adverse events of hepatic disorder were captured. Autoimmune hepatitis and drug-induced liver injury both presented positive signals across multiple statin drugs. Notably, atorvastatin had the most significant signal strength in cholestatic pruritus and bilirubin conjugation abnormal. Fluvastatin also showed notable signal strength in autoimmune hepatitis, while simvastatin had a relatively weaker signal strength for hepatic enzyme increased.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study discovered specific adverse event signal values, revealing potential hepatotoxic risks associated with the use of statin drugs. The results provide an important reference for the safe clinical use of drugs, help to improve the understanding of the safety of statins, and also provide a scientific basis for clinicians to make more accurate and safe decisions when making treatment plans.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1502791","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T08:11:23Z","timestamp":1736237483000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Hepatotoxicity of statins: a real-world study based on the US Food and Drug Administration Adverse Event Reporting System database"],"prefix":"10.3389","volume":"15","author":[{"given":"Bojing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e931418","DOI":"10.12659\/AJCR.931418","article-title":"Hepatotoxicity induced by fluvastatin: a reversible acute cholestatic liver injury","volume":"22","author":"Alanazi","year":"2021","journal-title":"Am. J. Case Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.14218\/JCTH.2021.00271","article-title":"Statin-induced liver injury patterns: a clinical review","volume":"10","author":"Averbukh","year":"2022","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/liv.13308","article-title":"Hepatotoxicity of statins and other lipid-lowering agents","volume":"37","author":"Bj\u00f6rnsson","year":"2017","journal-title":"Liver Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2021.05.016","article-title":"Trends in lipid-modifying agent use in 83 countries","volume":"328","author":"Blais","year":"2021","journal-title":"Atherosclerosis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"n1537","DOI":"10.1136\/bmj.n1537","article-title":"Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses","volume":"374","author":"Cai","year":"2021","journal-title":"BMJ"},{"key":"B6","volume-title":"Cardiovascular disease: risk assessment and reduction, including lipid modification","year":"2023"},{"key":"B7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13046-021-02041-2","article-title":"Statins: a repurposed drug to fight cancer","volume":"40","author":"Jiang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12016-020-08791-9","article-title":"Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways","volume":"60","author":"Koushki","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e3348","DOI":"10.7717\/peerj.3348","article-title":"Atorvastatin alters the expression of genes related to bile acid metabolism and circadian clock in livers of mice","volume":"5","author":"Li","year":"2017","journal-title":"PeerJ"},{"key":"B10","doi-asserted-by":"publisher","first-page":"7092414","DOI":"10.1155\/2018\/7092414","article-title":"Effect of stains on ldl reduction and liver safety: a systematic review and meta-analysis","volume":"2018","author":"Liang","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.pharmthera.2018.10.004","article-title":"Statins: adverse reactions, oxidative stress and metabolic interactions","volume":"195","author":"Liu","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.24425\/pjvs.2019.127095","article-title":"Influence of simvastatin on hepatocytes - histopathological and immunohistochemical study","volume":"22","author":"Mikiewicz","year":"2019","journal-title":"Pol. J. Vet. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/jcsm.12654","article-title":"Effects of statins on mitochondrial pathways","volume":"12","author":"Mollazadeh","year":"2021","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1111\/bcp.15757","article-title":"Rhabdomyolysis and statins: a pharmacovigilance comparative study between statins","volume":"89","author":"Montastruc","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12664-011-0092-x","article-title":"Overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis triggered by fluvastatin","volume":"30","author":"Nakayama","year":"2011","journal-title":"Indian J. Gastroenterol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.gastrohep.2017.05.010","article-title":"Autoimmune hepatitis (Immune-Mediated liver injury) induced by rosuvastatin","volume":"41","author":"S\u00e1nchez","year":"2018","journal-title":"Gastroenterol. Hepatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"103731","DOI":"10.1016\/j.critrevonc.2022.103731","article-title":"Statins and renal cell carcinoma: antitumor activity and influence on cancer risk and survival","volume":"176","author":"Santoni","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated side effects","volume":"67","author":"Thompson","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e47807","DOI":"10.7759\/cureus.47807","article-title":"Atorvastatin-induced autoimmune hepatitis: a case report","volume":"15","author":"Tse","year":"2023","journal-title":"Cureus"},{"key":"B22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11894-017-0584-7","article-title":"Use of statins in patients with chronic liver disease and cirrhosis: current views and prospects","volume":"19","author":"Vargas","year":"2017","journal-title":"Curr. Gastroenterol. Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e2320222","DOI":"10.1001\/jamanetworkopen.2023.20222","article-title":"Association of statin use with risk of liver disease, hepatocellular carcinoma, and liver-related mortality","volume":"6","author":"Vell","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"B24","doi-asserted-by":"publisher","first-page":"11687","DOI":"10.3390\/ijms222111687","article-title":"Statin-associated myopathy: emphasis on mechanisms and targeted therapy","volume":"22","author":"Vinci","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/17512433.2024.2311875","article-title":"Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system","volume":"17","author":"Xiao","year":"2024","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2147\/TCRM.S204860","article-title":"Association of atorvastatin with the risk of hepatotoxicity: a pilot prescription sequence symmetry analysis","volume":"15","author":"Zhang","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3987065","DOI":"10.1155\/2020\/3987065","article-title":"Comparative lipid-lowering\/increasing efficacy of 7 statins in patients with dyslipidemia, cardiovascular diseases, or diabetes mellitus: systematic review and network meta-analyses of 50 randomized controlled trials","volume":"2020","author":"Zhang","year":"2020","journal-title":"Cardiovasc Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1080\/0886022X.2021.1915799","article-title":"Efficacy of statins on renal function in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"43","author":"Zhao","year":"2021","journal-title":"Ren. Fail"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1502791\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T08:11:26Z","timestamp":1736237486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1502791\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":28,"alternative-id":["10.3389\/fphar.2024.1502791"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1502791","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"article-number":"1502791"}}